Literature DB >> 3100619

Experimental cutaneous leishmaniasis. II. A possible role for prostaglandins in exacerbation of disease in Leishmania major-infected BALB/c mice.

J P Farrell, C E Kirkpatrick.   

Abstract

Leishmania major infection in genetically susceptible BALB/c mice is associated with the development of chronic primary lesions as well as multiple metastatic lesions. Spleen cells from these mice were shown to have depressed in vitro responses to concanavalin A (Con A) that coincided with the development of indomethacin-sensitive suppressor cells. Depressed responses to Con A were noted as early as 1 wk after parasite inoculation and correlated with the increased production of prostaglandin E2 (PGE2) by spleen cells from infected mice. Mice induced by prior irradiation (550 rad) to heal infection did not develop indomethacin-reversible depression in responsiveness to Con A. Although macrophages appear to be the major source of PGE2 production, in vitro studies indicate that infection per se is not a sufficient stimulus to initiate prostaglandin (PG) synthesis, suggesting the involvement of other cell types. Mice treated in vivo with indomethacin exhibited significantly fewer metastatic lesions than control mice, suggesting that PG may play a role in the exacerbation of cutaneous disease in these animals.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3100619

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  An in vitro model for infection with Leishmania major that mimics the immune response in mice.

Authors:  M B Soares; J R David; R G Titus
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Leishmania donovani-Induced Prostaglandin E2 Generation Is Critically Dependent on Host Toll-Like Receptor 2-Cytosolic Phospholipase A2 Signaling.

Authors:  Amrita Bhattacharjee; Saikat Majumder; Shibali Das; Sweta Ghosh; Satabdi Biswas; Subrata Majumdar
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

Review 4.  Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view.

Authors:  Martin Olivier; David J Gregory; Geneviève Forget
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  Influence of parasite load on the ability of type 1 T cells to control Leishmania major infection.

Authors:  Brian Hondowicz; Phillip Scott
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

6.  Novel 17-kilodalton Leishmania antigen revealed by immunochemical studies of a purified glycoprotein fraction recognized by murine T lymphocytes.

Authors:  M M Rodrigues; M T Xavier; L Mendonça-Previato; M A Barcinski
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

7.  T-cell receptor/CD28 engagement when combined with prostaglandin E2 treatment leads to potent activation of human T-cell leukemia virus type 1.

Authors:  Nancy Dumais; Marie-Eve Paré; Simon Mercier; Salim Bounou; Susan J Marriot; Benoit Barbeau; Michel J Tremblay
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Combined treatment with interleukin-12 and indomethacin promotes increased resistance in BALB/c mice with established Leishmania major infections.

Authors:  Jian Li; Udaikumar M Padigel; Phillip Scott; Jay P Farrell
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 9.  The Th1/Th2-like switch in syphilitic infection: is it detrimental?

Authors:  T J Fitzgerald
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

Review 10.  Production of eicosanoids and other oxylipins by pathogenic eukaryotic microbes.

Authors:  Mairi C Noverr; John R Erb-Downward; Gary B Huffnagle
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.